10-K: Relmada Therapeutics Reports 2023 Annual Results, Provides Update on Clinical Programs

Relmada Therapeutics, a clinical-stage biotech company, reported its 2023 annual results, highlighting progress in its esmethadone and psilocybin programs, while also noting significant financial losses.

Summary

• Relmada Therapeutics is a clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) diseases.
• Their lead product candidate is esmethadone (REL-1017), an NMDA receptor antagonist being developed for depression and other potential indications.
• The company is also developing a modified-release formulation of psilocybin (REL-P11) for metabolic indications.
• Relmada reported a net loss of approximately $98.8 million for 2023, compared to a net loss of $157 million in 2022.
• The company's accumulated deficit as of December 31, 2023, was approximately $560.9 million.
• Research and development expenses decreased to $54.8 million in 2023 from $113.3 million in 2022, primarily due to the completion of Phase 3 trials.
• General and administrative expenses increased slightly to $48.9 million in 2023 from $47.9 million in 2022.
• The company had cash, cash equivalents, and short-term investments of approximately $96.3 million at the end of 2023.
• Relmada expects to complete enrollment in the RELIANCE II study and the RELIGHT study by the end of 2024, with top-line data from RELIANCE II expected in the second half of 2024.
• They also plan to initiate a Phase 1 trial for REL-P11 in obese patients in the first half of 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as the potential of the drug candidates and the intellectual property portfolio, the significant financial losses, failed Phase 3 trials, and reliance on third parties create a negative sentiment. The company is still in the early stages of development and faces significant risks.

Positives

• Esmethadone has shown robust efficacy in a Phase 2 trial with rapid onset of action.
• Human abuse potential studies for esmethadone showed a statistically significant difference versus oxycodone and ketamine, indicating low abuse potential.
• The company has a diversified portfolio with the development of psilocybin for metabolic indications.
• Relmada has a strong intellectual property portfolio with patents potentially extending beyond 2033.
• The long-term, open-label study of REL-1017 showed sustained improvements in depressive symptoms with good tolerability.

Negatives

• The company reported a significant net loss of $98.8 million for 2023.
• The RELIANCE I and RELIANCE III Phase 3 trials for esmethadone did not achieve their primary endpoints.
• The company has an accumulated deficit of approximately $560.9 million.
• The company has no commercial products and does not anticipate generating revenues for the foreseeable future.
• The company relies on third parties for manufacturing and clinical trials, which introduces risks.

Risks

• The success of the company is heavily dependent on the success of esmethadone, which is still in clinical development.
• Clinical trials may not be successful, and regulatory approvals are not guaranteed.
• The company may not be able to obtain or maintain orphan drug exclusivity for esmethadone.
• The active ingredients in esmethadone and psilocybin are controlled substances, which may limit supply and generate public controversy.
• The company relies on third parties for manufacturing and clinical trials, which introduces risks.
• The company may face product liability claims and may not be able to maintain product liability insurance.
• The company's license agreement for esmethadone could terminate under certain circumstances, including if the CEO is terminated without cause.
• The company has a history of losses and may never achieve or sustain profitability.
• The company may not be successful in hiring and retaining key employees.
• The company's stock price may be volatile.

Future Outlook

Relmada expects to complete enrollment in the RELIANCE II and RELIGHT studies by the end of 2024, with top-line data from RELIANCE II expected in the second half of 2024. They also plan to initiate a Phase 1 trial for REL-P11 in obese patients in the first half of 2024.

Management Comments

• Management believes that the company has sufficient funding to continue ongoing operations for at least 12 months from the filing of this annual report.
• Management is focused on further developing esmethadone as their priority program.

Industry Context

The document highlights the competitive landscape in the pharmaceutical and biotechnology industry, noting that Relmada competes with large, well-established companies. The company is targeting the large market for CNS diseases, which affects nearly 2 billion people globally. The document also notes the urgent need for improved, faster-acting antidepressant treatments.

Comparison to Industry Standards

• Relmada's approach to developing esmethadone as a rapidly acting, oral agent for depression is similar to that of Axsome Therapeutics with Auvelity and Johnson & Johnson with Spravato, both of which are also focused on rapid-acting treatments.
• The company's focus on NMDA receptor antagonism is a similar mechanism of action to ketamine and esketamine, but Relmada is aiming to avoid the adverse side effects associated with those drugs.
• The company's development of a modified-release psilocybin formulation for metabolic indications is a novel approach, as most psilocybin research is focused on psychiatric disorders.
• The company's reliance on third-party manufacturers and CROs is a common practice in the biotechnology industry, but it introduces risks that need to be managed.
• The company's financial losses are typical for a clinical-stage biotech company, as they are investing heavily in research and development without generating revenue from commercial products.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's financial losses and the need for additional funding.
• Employees may be affected by the company's financial performance and any potential restructuring or layoffs.
• Patients may benefit from the development of new treatments for depression and metabolic disorders, but there is no guarantee of success.
• Suppliers and creditors may face risks related to the company's financial stability and ability to meet its obligations.

Next Steps

• Complete enrollment in the ongoing RELIANCE II study, with top-line data expected in the second half of 2024.
• Complete enrollment in the RELIGHT study by the end of 2024.
• Initiate Phase 1 trial in obese patients with the modified-release formulation of psilocybin (REL-P11) in the first half of 2024.

Key Dates

Keywords

esmethadone, REL-1017, psilocybin, REL-P11, depression, MDD, clinical trials, biotechnology, NMDA antagonist, metabolic indications, CNS diseases, pharmaceuticals